Method of increasing intratumoral pHe and reducing acid-mediated invasion

Patent metadata

Field	Value
Publication number	US-10258607-B2
Application number	US-201213479638-A
Country	US
Kind code	B2
Filing date	May 24, 2012
Priority date	Nov 24, 2009
Publication date	Apr 16, 2019
Grant date	Apr 16, 2019

Abstract

A method of treating cancer or inhibiting metastasis in a subject by increasing intratumoral extracellular pH is presented. The method includes administering to the subject a therapeutically effective amount of a buffer having a pKa greater than 6.1. In an advantageous embodiment the pKa of the buffer is about 7.0. Examples of buffers for increasing extracellular pH include NaHCO 3 , 2-imidazole-1-yl-3-ethoxycarbonylpropionic acid (IEPA), cholamine chloride, N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), N-Tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES) and 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES). The method can further include the step of pretreating with one or more chemotherapeutic agents.

First claim

What is claimed is:

1. A method of treating at least one cancerous tumor in a patient having at least one cancerous tumor comprising:
administering 200 mM of 2-imidazole-1-yl-3-ethoxycarbonylpropionic acid (IEPA) to the patient wherein the IEPA is repeatedly and chronically orally administered;
wherein administration of the IEPA increases intratumoral extracellular pH (pHe) in the at least one cancerous tumor of the patient above pre-administration pHe levels that were obtained prior to initiation of any treatment with the IEPA;
wherein the increase in the intratumoral pHe of the at least one cancerous tumor treats the at least one cancerous tumor in the patient.

2. The method according to claim 1 , further comprising administering at least one chemotherapeutic agent to the patient simultaneously with the administration of the IEPA.

3. The method according to claim 1 , wherein the at least one cancerous tumor is selected from the group consisting of breast cancer, lung cancer, liver cancer, pancreatic cancer, prostate cancer, sarcomas, stomach cancer, testicular cancer, and ovarian cancer.

4. The method of claim 1 , further comprising administering at least one chemotherapeutic agent to the patient at a time period prior to the initiation of a first administration of the IEPA.

5. A method of inhibiting metastasis of at least one cancer cell in a patient having at least one cancer cell comprising:
administering 200 mM of 2-imidazole-1-yl-3-ethoxycarbonylpropionic acid (IEPA) to the patient wherein the IEPA is repeatedly and chronically orally administered;
wherein administration of the IEPA increases intratumoral extracellular pH (pHe) in the at least one cancer cell of the patient above pre-administration pHe levels that were obtained prior to initiation of any treatment with the IEPA;
wherein the increase in the intratumoral pHe of the at least one cancer cell inhibits metastasis of the at least one cancer cell in the patient.

6. The method of claim 5 , further comprising administering at least one chemotherapeutic agent to the patient simultaneously with the administration of the IEPA.

7. The method according to claim 5 , wherein the at least one cancer cell is selected from the group consisting of breast cancer cells, lung cancer cells, liver cancer cells, pancreatic cancer cells, prostate cancer cells, sarcomas, stomach cancer cells, testicular cancer cells, and ovarian cancer cells.

8. The method of claim 5 , further comprising administering at least one chemotherapeutic agent to the patient at a time period prior to the initiation of a first administration of the IEPA.

Assignees

• Gillies Robert J
• Morse David L
• Silva Ariosto Siqueira
• Ibrahim Hashim Arig A
• Gatenby Robert A
• Martinez Gary
• H Lee Moffitt Cancer Ct & Res

Inventors

• Gillies Robert J
• Morse David L
• Silva Ariosto Siqueira
• Ibrahim Hashim Arig A
• Gatenby Robert A
• Martinez Gary

Classifications

• A61P35/04

  specific for metastasis · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/4172 Primary

  Imidazole-alkanecarboxylic acids, e.g. histidine · CPC title

• A61K31/133

  having hydroxy groups, e.g. sphingosine · CPC title

• A61K31/255

  of sulfoxy acids or sulfur analogues thereof · CPC title